Pam Marcus, Ph.D.
Program Director, Clinical and Translational Epidemiology Branch
National Institutes of Health
National Cancer Institute
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
9609 Medical Center Drive, Rm. 4E608, MSC 9763
Bethesda, MD 20892
(For express delivery, use Rockville, MD 20850)
- Telephone: (240) 276-6901
- Fax: (240) 276-7921
- E-mail: email@example.com
- Cancer epidemiology and screening
- Cancer risk in persons with chronic conditions
- Operations and management of large, multicenter initiatives, including clinical trials
- Lung cancer
- Ph.D. - Epidemiology
University of North Carolina, Chapel Hill
- M.S. - Preventive Medicine
University of Wisconsin–Madison
- M.S. - Statistics
University of Wisconsin–Madison
Pam Marcus, an Epidemiologist in the Applied Research Program, is currently on detail in the Epidemiology and Genomics Research Program's (EGRP) Clinical and Translational Epidemiology Branch (CTEB). She is assisting CTEB in its efforts to develop a research agenda that addresses cancer risk in individuals with chronic conditions and diseases, as well as one that explores translation of new clinical/genomic cancer screening tests.
Pam began her career as an Epidemiologist in 1989. She received an M.S. in Statistics (1991) and an M.S. in Preventive Medicine (1993) from the University of Wisconsin-Madison. She received a Ph.D. in Epidemiology from the University of North Carolina at Chapel Hill in 1997, and was a Cancer Prevention Fellow from 1997 to 1999.
From 1999-2011, Pam resided in the Division of Cancer Prevention's Biometry Research Group. She worked on the National Lung Screening Trial and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, two large randomized controlled trials of the efficacy of various screening modalities. During that time, she published extensively on lung cancer screening. She came to ARP in 2011 to lead the PROSPR Initiative, an observational study of the breast, cervical, and colorectal cancer screening processes in clinical settings. She also worked with the Breast Cancer Surveillance Consortium (BCSC) investigators to facilitate establishment of the BCSC Research Resource, a data and analysis resource available for free to the research community and the general public.
Marcus PM, Kramer BS. Screening for prostate cancer with prostate-specific antigen (PSA): What's the evidence? In: Govindan R, ed. 2012 ASCO Educational Book. Alexandria, VA: American Society of Clinical Oncology; 2012.
The National Lung Screening Research Team. Reduced lung cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
Marcus PM, Gareen IF, Miller AB, Rosenbaum J, Keating K, Aberle DR, Berg CD. The National Lung Screening Trial's endpoint verification process: determining the cause of death. Contemp Clin Trials. 2011;32(6):834-40.
Marcus PM, Bergstralh EJ, Zweig MH, Harris A, Offord KP, Fontana RS. Extended lung cancer incidence follow-up in the Mayo Lung Project: additional support for overdiagnosis. J Natl Cancer Inst. 2006; 98:748-756.
Marcus PM, Bergstralh EJ, Fagerstrom RM, Fontana RS, Taylor W, Prorok PC. Lung cancer mortality in the Mayo Lung Project: the impact of extended follow-up. J Natl Cancer Inst. 2000;92:1308-1316.
Marcus PM. Television as a venue for cancer education: the General Hospital experience. J Cancer Educ. 2000;15:4.
Marcus PM, Newman B, Millikan RC, Moorman PG, Baird DD, Qaqish B. The association of adolescent cigarette smoking, alcoholic beverage consumption, environmental tobacco smoke, and ionizing radiation with subsequent breast cancer risk. Cancer Causes and Control. 2000; 11:271-278.